Lake Street analyst Brooks O’Neil lowered the firm’s price target on Joint Corp. to $30 from $50 and keeps a Buy rating on the shares after management reported preliminary Q2 results. Management believes the underlying fundamentals in their chiropractic market remain strong and “we sense this team is being aggressive in responding to the pressures currently being felt,” says the firm, which is reducing its forecast for this year and next.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JYNT:
- Joint Corp. price target lowered to $13 from $16 at Roth MKM
- Joint Corp. lowers Q2 revenue view to $115M-$118M from $123M and $128M
- The Joint Corp. Reports Preliminary Second Quarter 2023 Financial Results
- Joint Corp. reports Q2 EPS 1c, consensus 1c
- Fly Insider: Ingredion, ADP among week’s notable insider trades
